- The MHRA has provided authorization for an emergency supply of AZD1222, for the active immunization of individuals aged ≥18yrs. The approval recommends 2 doses administered with an interval of between 4 & 12wks
- The authorization is based on independent advice from its CHM following a rolling review of trial data that included an interim analysis of the P-III program led by the University of Oxford
- AstraZeneca aims to supply millions of doses in Q1 as part of an agreement with the government to supply ~100M doses in total. The company will continue the regulatory interactions across the globe for the next approvals
Click here to read full press release/ article | Ref: AstraZeneca | Image: Express Pharma
The post AstraZeneca’s AZD1222 Receives MHRA’s Emergency Supply Authorization in the UK first appeared on PharmaShots.